Canlyniadau Chwilio - Rabinder Prinjha

  • Dangos 1 - 4 canlyniadau o 4
Mireinio'r Canlyniadau
  1. 1
    Neuropilin-2 Is Required In Vivo for Selective Axon Guidance Responses to Secreted Semaphorins

    Neuropilin-2 Is Required In Vivo for Selective Axon Guidance Responses to Secreted Semaphorins gan Roman J. Giger, Jean-François Cloutier, Amar Sahay, Rabinder Prinjha, Dorothy V Levengood, Stephen E. Moore, Susan J. Pickering, David Simmons, Sohaila Rastan, Frank S. Walsh, Alex L. Kolodkin, David D. Ginty, Martin Geppert

    Cyhoeddwyd 2000
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes

    Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia acro... gan Kimberly N. Smitheman, Tesa Severson, Satyajit Rajapurkar, Michael T. McCabe, Natalie O. Karpinich, James J. Foley, Melissa B. Pappalardi, Ashley M. Hughes, Wendy S. Halsey, Elizabeth Thomas, Christopher Traini, Kelly Federowicz, Jenny Laraio, Fredrick M. Mobegi, Geraldine Ferron‐Brady, Rabinder Prinjha, Christopher L. Carpenter, Ryan G. Kruger, Lodewyk F.A. Wessels, Helai P. Mohammad

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

    Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors gan Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French, Sophie Cousin, Irene Braña, Phillippe Cassier, Víctor Moreno, Johann S. de Bono, Sara Harward, Geraldine Ferron‐Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J. Parr, Rabinder Prinjha, Christopher L. Carpenter, John Hilton, David S. Hong, Naomi B. Haas, Mark C. Markowski, Arindam Dhar, Peter J. O’Dwyer, Geoffrey I. Shapiro

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

    Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss gan Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien, Sarah V. Gerhart, Lorna H. Mitchell, Nicholas D. Adams, Nathalie Rioux, Trupti Lingaraj, Scott Ribich, Melissa B. Pappalardi, Niyant Shah, Jenny Laraio, Yan Liu, Michael Butticello, Chris Carpenter, Caretha L. Creasy, Susan Korenchuk, Michael T. McCabe, Charles F. McHugh, Raman P. Nagarajan, Craig D. Wagner, Francesca Zappacosta, Roland S. Annan, N.O. Concha, Roberta Thomas, Timothy K. Hart, J. Joshua Smith, Robert A. Copeland, Mikel P. Moyer, John Campbell, Kim Stickland, James E. Mills, Suzanne Jacques-O’Hagan, Christina J. Allain, Danielle Johnston, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Kerren K. Swinger, Ann Boriack-Sjodin, Thomas V. Riera, Gideon Shapiro, Richard Chesworth, Rabinder Prinjha, Ryan G. Kruger, Olena Barbash, Helai P. Mohammad

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: